Stretch-Induced Deformation as a Model to Study Dopaminergic Dysfunction in Traumatic Brain Injury.

In this study, we evaluated the effects of in vitro simulated TBI on human dopaminergic neurons. To simulate TBI, neurons were subjected to 0%, 5%, 10%, 15%, 25% and 50% deformation. 24 h after injury, cell viability and apoptosis were determined by lactate dehydrogenase (LDH) release and DNA fragmentation, as well as ethidium homodimer and caspase 3/7 staining. Dopamine (DA) levels were determined by ELISA. Levels of tyrosine hydroxylase (TH) and DA transporter (DAT) were determined by western blot. Only 50% stretch increased LDH release and ethidium homodimer staining, suggesting the induction of necrosis. On the contrary, 25% and 50% stretch increased DNA fragmentation while 15%, 25% and 50% increased caspase 3/7 staining, suggesting that moderate and severe TBI promote apoptosis. Levels of intracellular DA decreased in a stretch-dependent manner with 15%, 25% and 50% stretch, which were related with a decrease in TH expression. Extracellular DA levels increased only at 50%. Levels of DAT remained unchanged regardless of treatment. These data support the use of stretch as a model to simulate TBI in vitro in human dopaminergic neurons, replicating the acute effects of TBI in the dopaminergic system. PMID: 31529335 [PubMed - as supplied by publisher]
Source: Neurochemical Research - Category: Neuroscience Authors: Tags: Neurochem Res Source Type: research

Related Links:

Some wearable solutions exploiting on-body acceleration sensors have been proposed to recognize Freezing of Gait (FoG) in people affected by Parkinson Disease (PD). Once a FoG event is detected, these systems generate a sequence of rhythmic stimuli to allo...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
AbstractPurposePsychotic symptoms in Parkinson ’s disease are relatively common and include hallucinations, illusions, and delusions. Psychosis is a major cause of disability and is one of the most distressing symptoms for both patients and caregivers. The management of psychosis is often complex and challenging and involves determining the de gree and severity of psychotic symptoms and whether intervention is required. In this review, the authors describe the phenomenology and risk factors of Parkinson’s disease psychosis (PDP) and current evidence-based treatment options.Recent findingsIn randomized, double-b...
Source: Current Treatment Options in Psychiatry - Category: Psychiatry Source Type: research
Conclusions: To the best of our knowledge, this is the first study investigating verbal memory consolidation in PD. Results suggested that impairment is possibly related to the late phase of consolidation of verbal memory in neocortex.
Source: Journal of Clinical Neuroscience - Category: Neuroscience Source Type: research
Publication date: December 2019Source: Journal of Clinical Neuroscience, Volume 70Author(s): Hülya Olgun Yazar, Tamer Yazar, Murat CihanAbstractAimIn our study, we aimed to collect data for the hypothesis that Galectin-3 might be used as a new prognostic and therapeutic biomarker in Idiopathic Parkinson's Disease (IPD).MethodIn this prospective and cross-sectional study, the Unified Parkinson's Disease Rating Scale (UPDRS) and Modified Hoehn and Yahr (H&Y) scales were applied to each patient diagnosed as IPD according to the UK Brain Bank diagnostic criteria. The control group consisted of healthy individuals with the...
Source: Journal of Clinical Neuroscience - Category: Neuroscience Source Type: research
Condition:   Parkinson's Disease Intervention:   Behavioral: Wellness Recovery Program Sponsor:   Wake Forest University Health Sciences Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Parkinson Disease Intervention:   Other: hyperthermic baths Sponsor:   Nanjing First Hospital, Nanjing Medical University Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Parkinson's Disease Interventions:   Drug: Pimavanserin;   Other: Placebo;   Drug: Quetiapine Sponsor:   ACADIA Pharmaceuticals Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Parkinson's disease is characterized by the aggregation and spread of misfolded α-synuclein throughout the brain, though, as for all neurodegenerative conditions, there are many layers of cause and effect, and chronic inflammation and cellular dysfunction play noted roles as well. There has been some debate in recent years over whether the α-synuclein aggregation of Parkinson's disease begins in the gut or the brain, with evidence presented for both sides. The authors of this open access paper suggest that both are the case, and Parkinson's can be divided into two subtypes depending on the origin of α-syn...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs
Conclusions There is weak evidence for a positive effect of short-term whole-body vibration training on spasticity of lower limbs, mobility, balance, and postural control. Besides, positive effect of the long-term effect of whole-body vibration training on mobility in patients with neurological disorders. The optimal whole-body vibration training parameters in treating patients with neurological disorders remain unclear.
Source: American Journal of Physical Medicine and Rehabilitation - Category: Rehabilitation Tags: Original Research Articles Source Type: research
CONCLUSIONS: In this review, biological and chemical knowledge of melatonin, its experimental effects, and the clinical impact on patients with neurological disorders were described. According to all of the beneficial results obtained from experimental and clinical trials, melatonin may have a prophylactic and therapeutic effect on neurological diseases. Strong collaboration between neurologists and health service policy makers is needed to encourage use of melatonin in the patients suffering from neurological diseases. Melatonin may be the solution we have been looking for. PMID: 31718830 [PubMed - as supplied by publisher]
Source: Revue Neurologique - Category: Neurology Tags: Rev Neurol (Paris) Source Type: research
More News: Brain | Neurology | Neuroscience | Parkinson's Disease | Study